Am Fam Physician. 2022;105(5):542-543
Author disclosure: No relevant financial relationships.
MyProstateScore (MPS; also referred to as Michigan Prostate Score) combines serum prostate-specific antigen (PSA) levels with the urinary biomarkers prostate cancer antigen 3 (PCA3) and TMPRSS2: ERG gene fusion to estimate the risk of prostate cancer. MPS is marketed as a tool for determining the likelihood of detecting clinically significant prostate cancer on biopsy.1–3 It may help patients and physicians decide whether to proceed with a prostate biopsy.
| Test | Indication | Population | Cost* |
|---|---|---|---|
| MyProstateScore | Estimate risk of clinically significant prostate cancer (grade group 2 or higher) to determine need for prostate biopsy | Adults who are referred for prostate biopsy | $760 |
Already a member/subscriber?
Log In
Subscribe
From $165- Immediate, unlimited access to all AFP content
- More than 130 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
Purchase Access:
Learn More
